TCM
AEGR

Tamarack Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Tamarack Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-400,000
Closed -$11.7M – 37
2014
Q2 		$11.7M Buy
+400,000
New +$14.9M 2.38% 14

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tamarack Capital Management's AEGR Position: Q3 2014 in Review

Tamarack Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 400,000 shares — an estimated $11.7M sold.

Tamarack Capital Management first reported a position in AEGR in Q2 2014 and held it in 1 quarter. The position peaked at $11.7M in Q2 2014. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • Tamarack Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Tamarack Capital Management sold 400,000 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $11.7M.
  • Tamarack Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Tamarack Capital Management's Aegerion Pharmaceuticals position peaked at $11.7M in Q2 2014.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on Tamarack Capital Management's 13F filing for Q3 2014, filed 7 Nov 2014.